Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Michael Davidson
AddedFeb 19, 2024
UpdatedJun 14, 2026
Michael Davidson

Michael Davidson

Co-Founder & Executive Chairman, SonoThera

Michael Davidson's Career

SonoThera
SonoThera

South San Francisco, CA, US

Co-Founder & Executive Chairman
Tenax Therapeutics
Tenax Therapeutics

Morrisville, NC, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Michael Davidson's Career

SonoThera
SonoThera
Series B$185.8M502021South San Francisco, CA, US
Co-Founder & Executive Chairman

Recent news

SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic MedicinesSonoThera · 2026
Big Pharma-backed SonoThera sounds off with $125M series B for bubble-based genetic deliveryFierce Biotech · 2026
SonoThera Presents New Preclinical Data at MDA 2026 Highlighting RIPPLE as an Efficient, Scalable, Nonviral Platform for Full-Length Dystrophin Delivery in DMDSonoThera · 2026

Leadership at SonoThera

Dustin LuettgenDustin LuettgenDirector of Legal & Intellectual Property
Sandra RivasSandra RivasVice President, Head of Regulatory
Shawn FuShawn FuVice President, Corporate Development, Head of Strategy
Nancy JorgesenNancy JorgesenSenior Vice President, Head of Product Development
Ivan KrivegaIvan KrivegaVice President, Gene Therapy
Marco CrosariolMarco CrosariolVice President, Head of Operations
Tenax Therapeutics
Tenax Therapeutics
Public$99.3M82008Morrisville, NC, US
Board Member· Board

Leadership at Tenax Therapeutics

Gerry ProehlGerry ProehlBoard Member
Declan DooganDeclan DooganBoard Member
Chris GiordanoChris GiordanoCEO

Similar to Tenax Therapeutics

Lung BiotechnologyLung BiotechnologySilver Spring, MD, USPharmaceuticalsest. 1997Lung BiotechnologySilver Spring, MD, US · est. 1997

Lung Biotechnology PBC: Researching, developing, and marketing therapies for pulmonary arterial hypertension.

Public125
Exodos Life SciencesExodos Life SciencesPrinceton, NJ, USPharmaceuticalsest. 2009Exodos Life SciencesPrinceton, NJ, US · est. 2009

Exodos Life Sciences: Developing innovative pharmaceutical products since 2009, based in North Carolina.

Pre-Seed · $2.4M5
United TherapeuticsUnited TherapeuticsSilver Spring, MD, USPharmaceuticalsest. 1996United TherapeuticsSilver Spring, MD, US · est. 1996

United Therapeutics, a Maryland-based biotech firm, develops pharmaceuticals for vascular diseases using synthetic prostacyclin.

Public985
TheracosTheracosMarlborough, MA, USPharmaceuticalsest. 2000TheracosMarlborough, MA, US · est. 2000

US-based Theracos, Inc. is a pharmaceutical R&D firm, developing novel therapies for unmet medical needs since 2000.

Private Equity · $118.1M75

Michael Davidson's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Michael Davidson

Michael BrunoMichael BrunoCEO at XXXXXMichael WestMichael WestCEO at Rothman InstituteHaim AvivHaim AvivBoard Member · PharmosPhilip MichaelPhilip MichaelCo-Founder · SharebertMichael MuchnickiMichael MuchnickiBoard Member · Windsor Health GroupDavid UrsoDavid UrsoCEO · Lite Strategy